

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州藥業股份有限公司

Guangzhou Pharmaceutical Company Limited

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Guangzhou Pharmaceutical Holdings Limited (“GPHL”), the controlling shareholder of Guangzhou Pharmaceutical Company Limited (the “Company”), is planning for a major assets reorganization (the “Event”) involving the Company. The Company has applied for a suspension of trading in the A shares of the Company at The Shanghai Stock Exchange with effect from 7 November 2011.

During the period of suspension in the dealing of its shares, the Company published the announcements dated 7 November 2011, 11 November 2011, 18 November 2011 and 25 November 2011 in the Shanghai Securities News, the Securities Times and on the website of The Shanghai Stock Exchange (www.sse.com.cn) and the contents of which have also been reproduced and published as overseas regulatory announcements on the website of The Stock Exchange of Hong Kong Limited. Meanwhile, the Company has been actively worked on the Event with GPHL and the relevant parties.

The Event involves the assets reorganization among GPHL, the Company and Guangzhou Baiyunshan Pharmaceutical Company Limited, another subsidiary of GPHL, which may involve mergers and acquisitions.

The Company originally planned for resumption of trading in the A shares on 7 December 2011. However, in view of the uncertainties about the Event, which involves a broader level and requires a longer period for discussing, demonstrating, finalising the Event and consulting the relevant authorities, therefore, the Company has continued to apply for a suspension of trading in the A shares of the Company at The Shanghai Stock Exchange with effect from 7 December 2011 in order to secure the interests of investors.

During the period of suspension in the dealing of its shares, the Company will fulfill its disclosure obligations in respect of the progress of the Event on a timely basis, and make further announcements regarding the progress of the Event every week. The Company will publish the announcement and resume trading of its shares when the Event is confirmed.

The Board of
Guangzhou Pharmaceutical Company Limited

Guangzhou, the PRC, 2 December 2011

As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Li Chuyuan, Mr. Shi Shaobin and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.